Mary Desane
Psychiatric/Mental Health, Adult · Tinton Falls, NJNPI 1497058275
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 52.3% of the total. Among psychiatric/mental health, adult clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $61.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$989
- Teva Pharmaceuticals USA, Inc.$380
- Alkermes, Inc.$279
- AbbVie$159
- Otsuka America Pharmaceutical, Inc.$32
- Johnson & Johnson$24
- plus $29 from 2 others
What the payments were for
- Food & beverage$1,79095%
- Education$1015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $989 |
| Teva Pharmaceuticals USA, Inc. | 5 | $380 |
| Alkermes, Inc. | 6 | $279 |
| AbbVie | 4 | $159 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$595
- ARISTADA$445
- AUSTEDO$125
- Austedo XR$122
- VRAYLAR$116
- ARISTADA INITIO$111
How this compares
$1,891 in reported general payments places this provider in the 90th percentile of 35 psychiatric/mental health, adult providers in New Jersey.
See all psychiatric/mental health, adult providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 56 | $83,154 |
| AustedoDeutetrabenazine | 12 | $63,421 |
| Invega SustennaPaliperidone Palmitate | 17 | $59,954 |
| Abilify MaintenaAripiprazole | 19 | $55,229 |
| FanaptIloperidone | 25 | $50,365 |
| VraylarCariprazine Hcl | 22 | $44,179 |
| NuedextaDextromethorphan Hbr/Quinidine | 32 | $38,099 |
| CaplytaLumateperone Tosylate | 21 | $31,427 |
| Aripiprazole | 509 | $29,097 |
| Risperidone | 1,836 | $25,535 |
| Paliperidone ErPaliperidone | 82 | $22,521 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $21,026 |
| Fluvoxamine Maleate | 310 | $20,919 |
| Divalproex Sodium ErDivalproex Sodium | 382 | $19,040 |
| Oxcarbazepine | 233 | $15,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $32 | $138,38275 claims |
| Johnson & JohnsonInvega Sustenna, Concerta | $24 | $65,69429 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $380 | $63,42112 claims |
| AbbVieVraylar | $159 | $44,17922 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $989 | $31,42721 claims |
| Alkermes, Inc.Lybalvi | $279 | $21,02614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 psychiatric/mental health, adult providers in New Jersey.
Other psychiatric/mental health, adult in Tinton Falls
- Frances BurnsLanoka Harbor$10K
- Jennifer Minnick-BrennanShrewsbury$5K
- Diane Goldblum GraffLinwood$2K
- Susan EganUpper Montclair$1K
- Barbara WrenVoorhees$1K
- Ann RhaticanCedar Knolls$1K
- Andrea CochranVoorhees$1K
- Susan FranklinGalloway$776
- Karen MoosviColts Neck$642
- Chris DoerrParamus$597
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.